Laura Mulloy, DO
Nephrology · Augusta, GANPI 1376652388
Payments from drug & device makers
Across 316 payments — averaging $2818.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$529K
- Vertex$245K
- Aurinia Pharma U.S., Inc.$40K
- E.r. Squibb & Sons, L.L.C.$39K
- Bayer$33K
- Cipla USA Inc.$1K
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 106 | $528,962 |
| Vertex | 10 | $244,864 |
| Aurinia Pharma U.S., Inc. | 17 | $39,945 |
| E.r. Squibb & Sons, L.L.C. | 8 | $38,884 |
| Bayer | 16 | $33,017 |
| Cipla USA Inc. | 2 | $1,035 |
| AstraZeneca(2 entities) | 43 | $852 |
| Vifor Pharma, Inc. | 15 | $376 |
| Otsuka America Pharmaceutical, Inc. | 8 | $277 |
| Mallinckrodt Hospital Products Inc. | 9 | $269 |
| Amgen | 9 | $234 |
| Fresenius USA Marketing, Inc. | 11 | $209 |
| Calliditas Therapeutics US Inc. | 4 | $197 |
| Travere Therapeutics, Inc. | 9 | $189 |
| OPKO Pharmaceuticals, LLC | 7 | $152 |
| Astellas Pharma US Inc | 4 | $126 |
| Renalytix AI, Inc. | 5 | $122 |
| Veloxis Pharmaceuticals, Inc. | 5 | $120 |
| Mallinckrodt Enterprises LLC | 2 | $111 |
| Ardelyx, Inc. | 4 | $91 |
| La Jolla Pharmaceutical Company | 1 | $77 |
| Merck | 3 | $70 |
| Novartis | 3 | $66 |
| Akebia Therapeutics Inc | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Melinta Therapeutics, LLC | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| AbbVie | 1 | $13 |
How this compares
$890,538 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Augusta
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Matthew DiamondAugusta$815K
- Devesh PatelAugusta$279K
- Don WilliamsonAugusta$116K
- Syed BabarAugusta$63K
- James StenardAugusta$13K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.